Atom Investors LP reported FULGENT GENETICS INC (FLGT) in 4 quarterly 13F filings from 2024 Q1 through 2025 Q3. Peak portfolio weight reached 0.05% in 2024 Q1. The latest visible filing shows FLGT at 0.03% of the fund.
This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.
This page is designed to answer the real investor question behind a 13F filing: how meaningful was Atom Investors LP's position in FULGENT GENETICS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.
FLGT was reported at 0.03% of portfolio in the most recent visible filing.
Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.
Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.
Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.
As of 2026 Q1 β sorted by position size
These are the practical questions this page is built to answer before you even open the full history table.
Atom Investors LP reported FLGT across 4 quarterly 13F filings, from 2024 Q1 through 2025 Q3.
The largest reported portfolio weight for FLGT was 0.05% in 2024 Q1.
The most recent filing on this page is 2025 Q3, when Atom Investors LP reported 18,965 shares, equal to 0.03% of portfolio, with an estimated market value of $429K.
The chart compares Atom Investors LP's quarterly FLGT portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.
Based on 13F filing dates vs. subsequent FLGT price moves, Atom Investors LP correctly timed 1 out of 3 reported position changes (33%).